TScan Therapeutics, Inc.
Waltham, Massachusetts, United States · Biotechnology, Health Care, Medical
TScan Therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform
Key facts
- Headquarters
- Waltham, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (TCRX)
- Website
- tscan.com
- Company page
Recent activity at TScan Therapeutics, Inc.
- : SEC 8-K (5.02): On October 13, 2026, Garry Nicholson and Gabriela Gruia, M.D. resigned from the Board of Directors of TScan Therapeutics, Inc., effective immediately. Their resignations were not due to any disagreements with the company. In light of these resignations, Stephen Biggar and R. Keith Woods were appointed to the Nominating and Corporate Governance Committee as member and chairperson, respectively, also effective October 13, 2026. The board now includes R. Keith Woods, Katina Dorton, and Stephen Biggar on the NCG Committee, while the Audit Committee comprises Katina Dorton, Barbara Klencke, and R. Keith Woods. These changes reflect a significant shift in the Board's composition at a critical juncture for the company.
- : SEC 8-K (5.02): The filing reports the departure of two key executives from TScan Therapeutics, Inc.: Jason A. Amello, who will cease serving as Chief Financial Officer, and Chrystal Louis, M.D., MPH, who will cease serving as Chief Medical Officer. Both executives entered into Confidential Separation Agreements on September 24 and September 25, 2026, respectively, with their employment terminating on the earlier of November 1, 2026 or the date they commence other roles. Mr. Amello is entitled to an $85,000 cash award contingent upon achieving a company milestone, while Dr. Louis is entitled to a $125,000 cash award under similar conditions. The agreements ensure continued salary and benefits until the Separation Dates and detail the ongoing obligations of the company. These changes are part of a strategic reorganization aimed at improving company operations.
- : SEC 8-K (5.02): On September 8, 2026, TScan Therapeutics, Inc. approved a retention program aimed at retaining key employees, specifically targeting Dr. Gavin MacBeath, the CEO, and Dr. Zoran Zdraveski, the Chief Legal and Strategy Officer. The program includes cash awards and the potential for future equity-based awards under the Amended and Restated 2021 Equity Incentive Plan. This initiative is crucial for the company's strategic stability and retaining essential talent during a critical phase of operations, underscoring the company's commitment to maintaining leadership continuity.
- : SEC 8-K (5.02): This filing reports the departure of Jason A. Amello, the Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Chief Medical Officer, as part of a strategic reorganization effective September 2, 2026. Mr. Amello is entitled to 12 months of his base salary and COBRA premium payments for himself and his dependents, while Dr. Louis is similarly entitled to 12 months of base salary plus any unpaid target bonus for fiscal year 2025, contingent upon their execution of releases in favor of the Company. Additionally, Gavin MacBeath, Ph.D., the Company's Chief Executive Officer, has taken over as the principal financial officer and principal accounting officer as of the same date.
- : SEC 8-K (1.02):
- : SEC 8-K (8.01): On June 22, 2026, the Company provided an update regarding its ongoing heme malignancies clinical program, specifically sharing initial data from Cohort C of the ALLOHA™ Phase 1 study evaluating TSC-101 in patients undergoing allogeneic hematopoietic cell transplantation. Notably, 19 patients were enrolled with a ~90% manufacturing success rate. As a result, 14 patients received their first infusion of TSC-101, with most achieving complete donor chimerism within ~3 weeks. The report highlights the safety and tolerability of TSC-101 infusions, consistent with previous cohorts. This advancement may significantly impact the treatment landscape for patients with heme malignancies, underscoring the Company's ongoing commitment to innovation in this area.
- : SEC 8-K (5.02): On March 31, 2026, Leiden Dworak notified TScan Therapeutics, Inc. of his resignation as Vice President of Finance and principal accounting officer, effective April 10, 2026. His departure is noted to involve no disagreements regarding the company's operations. In response, the Board appointed Jason A. Amello, the current Chief Financial Officer, as the new principal accounting officer, also effective April 10, 2026. Mr. Amello will not receive additional compensation for this role and there are no changes to his existing compensatory arrangements as a result of this appointment.
- : SEC 8-K (7.01): On January 12, 2026, TScan Therapeutics, Inc. made available a corporate presentation intended for use in potential meetings coinciding with the 44th Annual J.P. Morgan Healthcare Conference. The presentation will be used during the week of January 12, 2026, and is aimed at engaging with investors, analysts, and other participants in the conference. The presentation, labeled as Exhibit 99.1, will also be made publicly available on the company's investor relations website. This activity is significant as it presents the opportunity for the Company to attract investment and engage with stakeholders in the healthcare sector.
- : SEC 8-K (5.02): On November 25, 2025, TScan Therapeutics, Inc. approved a key employee retention program to incentivize vital personnel. This program, endorsed by the Compensation Committee, includes cash awards and equity-based awards to key employees, specifically targeting CEO Gavin MacBeath, CFO Jason A. Amello, and CMO Chrystal Louis. The cash awards total $399,000 for Dr. MacBeath, $170,000 for Mr. Amello, and $250,000 for Dr. Louis, with payments contingent upon achieving a specific milestone related to their pivotal trial of TSC-101. Additionally, they will receive restricted stock units (RSUs) of 1,000,000, 270,000, and 650,000, respectively, to vest under certain conditions linked to the milestone's success and continued service. This strategic initiative underlines the company's commitment to retaining critical leadership during pivotal development phases.
- : SEC 8-K (5.02): On November 25, 2025, TScan Therapeutics, Inc. approved a Retention Program aimed at retaining key employees critical to the company's operations. The program includes cash awards and the potential for future equity-based awards under the Amended and Restated 2021 Equity Incentive Plan. Significant participants in this program are Gavin MacBeath, Ph.D. (CEO), Jason A. Amello (CFO), and Chrystal Louis, M.D., M.P.H. (CMO). This strategic move reflects the company's intention to maintain critical leadership during pivotal development phases, thereby enhancing stability and focus in its ongoing projects.
TScan Therapeutics, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2021 | Venture | $100.0M |
| Jul 2019 | Venture | $23.3M |
Leadership
- David Southwell, Executive Officer, Director
- Christoph Westphal, Director
- Nandita Shangari, Director
- Andrew Hedin, Director
- Timothy Barberich, Director
- Ittai Harel, Director
- Doug Fambrough, Director
- Brian Silver, Director
- Christoph Westphal, Director
- Timothy Barberich, Director
- Hannes Smarason, Director
- Campbell Murray, Director
Verified email and direct lines for TScan Therapeutics, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
TScan Therapeutics, Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
TScan Therapeutics, Inc. in the news
- TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors - Yahoo Finance (Sep 02, 2026)
- Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech (Aug 19, 2026)
- Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Business Wire (Jun 03, 2026)
- TScan Therapeutics sheds majority of staff, pauses Phase 3 trial amid funding shortfall - The Business Journals (Sep 02, 2026)
- TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Yahoo Finance (Jun 24, 2026)
- TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance (Aug 12, 2026)
- TScan Therapeutics cuts 75% of workforce, pauses Phase 3 ALLOHA-2 trial for TSC-101 - The Clinical Trial Vanguard (Sep 03, 2026)
- TScan cuts 75% of workforce while shifting focus to solid tumor program - BioSpace (Sep 03, 2026)
Companies similar to TScan Therapeutics, Inc.
- Navion Neurosciences · Biotechnology, Health Care, Medical, Therapeutics
- Acrivon Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
- NYU Langone Health · Biotechnology, Health Care, Medical, Therapeutics
- Compugen · Biotechnology, Health Care, Medical, Therapeutics
- Immuneering · Biotechnology, Health Care, Medical, Therapeutics
About TScan Therapeutics, Inc.: questions and answers
What does TScan Therapeutics, Inc. do?
TScan Therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform
Where is TScan Therapeutics, Inc. headquartered?
TScan Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States.
Has TScan Therapeutics, Inc. raised funding?
Yes. Fundz has recorded 2 funding events for TScan Therapeutics, Inc.. The most recent, $100.0M, was in Jan 2021.
What is the latest news on TScan Therapeutics, Inc.?
On Oct 16, 2026, SEC 8-K (5.02): On October 13, 2026, Garry Nicholson and Gabriela Gruia, M.D. resigned from the Board of Directors of TScan Therapeutics, Inc., effective immediately. Their resignations were not due to any disagreements with the company. In light of these resignations, Stephen Biggar and R. Keith Wo
Is TScan Therapeutics, Inc. a public company?
Yes. TScan Therapeutics, Inc. is publicly traded under the ticker TCRX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy